Indoco Remedies stock gained over 4% today

Mumbai, July 24, 2025 – Indoco Remedies has got EU GMP certification for its Goa Plant II. The EU GMP Compliance Certificate is issued by the EU Health Authorities ensures that the site complies with the requirements of good manufacturing practices.

Indoco Remedies’ stock closed the day today, 24th July, up by 4.45% at Rs 325.

Stock Performance Snapshot

At 3:56 pm IST on July 24, the stock was trading at ₹319.40, up ₹8.25 from its previous close of ₹311.15. The share was trading in the range of ₹336.00 and ₹291.00 (high and low) with a total traded value of ₹ 36.44 crore.

Strategic Certification: EU GMP for Goa Plant II

Indoco received the EU GMP certificate for its sterile drug product manufacturing facility located at Verna Industrial Estate, Goa. This development strengthens the company’s compliance credentials for global supply and enhances its regulatory standing with European customers.

Aditi Panandikar, Managing Director of Indoco Remedies, stated:

“This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies. We remain fully committed to adhering to cGMP standards and consistently delivering quality products to customers and patients worldwide”.

Financial Snapshot

Despite a negative EPS of ₹-0.95 and a ROE of -0.76%, it appears that mean reversion is kicking in, as the stock saw buying interest, likely due to news of a significant regulatory update signalling a turnaround. The PE/PB ratio stands at -340.53/2.61; the turnover is ₹91.17 lakh; and the trade quantity is 0.29 lakh. The CEPS (TTM) is a worthy ₹9.70, which highlights that there is cash, even if earnings are currently in disarray.

About Indoco Remedies Ltd

Indoco Remedies is a research-driven pharmaceutical company with a turnover exceeding USD 180 million, employing over 6,000 professionals, including more than 400 scientists. It operates 11 manufacturing facilities-7 for finished dosages and 4 for APIs-approved by global regulators, including the USFDA and UK-MHRA. The company commands a strong domestic prescription base across multiple therapeutic segments and has significant global partnerships.

REF: https://www.bseindia.com/xml-data/corpfiling/AttachLive/5a04759c-e2e6-482d-bf54-1920cbb1711c.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations